Biomedical engineer Leyla Soleymani’s team was responsible for the hardware, including the chip that reads the sample.
Researchers at McMaster and Brock universities have created the prototype for a hand-held device to measure a biomarker for cancer, paving the way for home-based cancer monitoring and to improve access to diagnostic testing.
The device works much like the monitors that people with diabetes use to test their blood-sugar levels and could be used in a medical clinic or at home, all without lab work, greatly simplifying the process for testing blood for cancer’s signature.
A user would mix a droplet of blood in a vial of reactive liquid, then place the mixture onto a strip and insert it into a reader. In minutes, the device would measure an antigen that indicates the degree to which cancer is present.
The prototype has been designed to monitor prostate specific antigen (PSA) and the technology can readily be adapted to measure other markers, depending on the form of cancer or other chronic disease.
The ability to collect such information at home would make the daily lives of patients much easier while also generating accurate, shareable, up-to-the-minute results to guide their doctors in shaping care and treatment – all at a lower cost to the health-care system.
The device would also allow patients to continue to monitor their health after treatment.
The prototype was created by a research collaboration led by McMaster’s Leyla Soleymani, a biomedical engineer and Canada Research Chair in Miniaturized Biomedical Devices, and Brock’s Feng Li, an associate professor of chemistry who leads a bioanalytical chemistry lab.
Soleymani’s team (also including Sarah Traynor and Richa Pandey) was responsible for the hardware, including the chip that reads the sample, while Li’s team (also including Guan Wang) created the technology that analyzes the sample.
“This is another step toward truly personalized medicine,” Soleymani says. “We’re getting away from centralized, lab-based equipment for this kind of testing.
“This would make monitoring much more accessible and cut down on the number of times patients need to leave home to provide blood samples.”
Once commercialized, this device will be a paradigm shift for cancer diagnosis and prognosis, Li says.
“Since this device is a lot more accessible and user-friendly than conventional technologies, patients will be more willing to use it, which can improve clinical outcomes and save lives.”
The researchers’ proof-of-concept work is described in an article published in the journal Angewandte Chemie. The invention will need to be tested more broadly before earning the regulatory approvals that would permit commercial manufacturing
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Global Cancer Biomarkers Market Poised to Surge USD 26,000 Million By 2024on November 26, 2020 at 10:42 pm
The market research report titled Global Cancer Biomarkers Market Poised to Surge USD 26 000 Million By 2024 and published by Zion Market Research provides an insightful comprehension about the growth ...
- Lynparza® (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Canceron November 25, 2020 at 9:52 am
Lynparza is the first targeted treatment approved in biomarker-selected prostate cancer validated by a Phase III trial1 MISSISSAUGA, ON, Nov. 25, ...
- New protocols, precision approaches ahead for lung canceron November 24, 2020 at 8:45 pm
Scientists at Fred Hutch are working towards a less invasive, more informative biopsy technique as well as a more precise protocol to identify potential treatments for people with lung cancer, the ...
- Cancer Biomarkers Market Research Report by Type, by Product Type, by End-Use Industry – Global Forecast to 2025 – Cumulative Impact of COVID-19on November 24, 2020 at 2:35 am
Cancer is one of the leading diseases with which large number of population is being affected in many countries. Cancer ...
- Expert: Europeans ‘effectively denied access’ to decisive cancer biomarkerson November 23, 2020 at 10:54 pm
Biomarker testing holds the potential to revolutionise early diagnosis and prevention of cancer. But the EU has not yet managed to fully capitalise on these advances, according to health experts.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Cancer biomarker detector
- November Is Lung Cancer Awareness Month! Here's How Medical Advances Are Lowering Deathson November 28, 2020 at 8:49 pm
November is Lung Cancer Awareness Month! Lung cancer is the leading cause of cancer death of men and women in the U.S. In 2020 alone, an estimated 1.8 million cases will be diagnosed, claiming the ...
- Glowing biosensor to detect an aggressive lung canceron November 26, 2020 at 3:49 am
A light-emitting graphene-based biosensor can help diagnose small-cell lung cancer (SCLC), the most aggressive form of lung cancer 1. The biosensor could help detect the deadly cancer by measuring ...
- Lucintel Anticipates that North America Will be the Fastest Growing Region in the Cancer Biomarker Marketon November 23, 2020 at 1:01 am
DALLAS, TX / ACCESSWIRE / November 23, 2020 / According to a new market report published by Lucintel, the future of the cancer biomarker market looks promising with opportunities in the diagnostics, ...
- A New Device Aims to Make Breast Cancer Screenings Part of Your Regular Self-Care Ritualon November 20, 2020 at 5:47 pm
A 23-year-old inventor has been awarded the James Dyson Award for the creation of a new at-home breast cancer screening device that could eventually give more women access to early detection.
- Biocept's assays viable and sensitive for detecting tumor cells and biomarkerson November 20, 2020 at 11:02 am
Biocept (NASDAQ:BIOC) +2% in premarket, after announcing results of a study analyzing cerebrospinal fluid (CSF) samples in patients with primary lung or breast cancer with either brain or ...